Tiazac (diltiazem hydrochloride)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved February 1998

Specific Treatments:

chronic stable angina

Find Related Trials for The Following Conditions

General Information

Tiazac (diltiazem HCl) has been approved for the treatment of chronic stable angina. Tiazac was previously approved for the treatment of hypertension. Tiazac, a once-daily calcium channel blocker, has been proven highly effective in important angina efficacy parameters; it significantly reduces both angina attack rates and nitroglycerin consumption. Tiazac's central effects and peripheral vasodilating action balances oxygen supply and demand producing significantly greater increases in total duration of exercise compared to placebo. Additionally Tiazac effectively reduces blood pressure of hypertensive patients over the 24-hour dosing interval with a side-effect profile comparable to placebo, even when dosed up to 360 mg.

Clinical Results

Tiazac has been shown to significantly reduce both angina attack rates and nitroglycerin consumption. Tiazac's central effects and peripheral vasodilating action balanced oxygen supply and demand producing significantly greater increases in total duration of exercise compared to placebo. Additionally, Tiazac effectively reduced blood pressure of hypertensive patients over a 24-hour dosing interval.

Side Effects

Side Effects: The side-effect profile is comparable to placebo, even when dosed up to 360 mg.

Mechanism of Action

Tiazac (diltiazem HCl) is a once-daily calcium channel blocker.